• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Jaguar Health Closes Bridge Financing Under Nasdaq Rules

    ACCESSWIRE

    83.33% of Vets Support Jaguar Health`s Canalevia-CA1 for Dog

    ACCESSWIRE

    Jaguar Health Meets FDA on Phase 3 OnTarget Study Results

    ACCESSWIRE

    Jaguar Health to Present at Conference and Hold Webcast on Q4 2024

    ACCESSWIRE

    Jaguar Health Announces Reverse Stock Split

    ACCESSWIRE

    Jaguar Adopts Stockholder Rights Plan To Protect Long-Term Value

    ACCESSWIRE

    Jaguar Extends NP-300 Deal For Cholera, Tropical Disease PRV

    ACCESSWIRE

    Jaguar Health to Present at Emerging Growth Conference on Feb 18

    ACCESSWIRE

    Magdalena Biosciences to Present at BIO CEO & Investor Conference

    ACCESSWIRE

    Jaguar Health Doses 1st Patient in Short Bowel Syndrome Trial

    ACCESSWIRE

    Jaguar Health Backs Crofelemer For GLP-1 GI Side Effects

    ACCESSWIRE

    Jaguar Health Doses 1st Patient In Evaluating Crofelemer For MVID

    YAHOOFINANCE

    Jaguar`s New Employee Inducement Grants Under Nasdaq LR 5635(c)(4)

    ACCESSWIRE

    Jaguar Health to Present at Lytham Summit & Biotech Showcase in Jan

    ACCESSWIRE

    Jaguar Announces Coca Leaf Import from Peru for Research

    ACCESSWIRE

    Phase 2 Study Evaluates Jaguar’s Crofelemer for MVID

    ACCESSWIRE

    FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer

    ACCESSWIRE

    Ladenburg Hosts Showcase On Jaguar`s Rare Disease Research

    ACCESSWIRE

    Jaguar’s Crofelemer Show Positive Results For CTD In Breast Cancer

    ACCESSWIRE

    Crofelemer for Cancer Therapy-Related Diarrhea Presented at SABCS

    ACCESSWIRE

    Trial Begins For Crofelemer In Short Bowel Syndrome With IF

    ACCESSWIRE

    Jaguar Health’s Canalevia-CA1 Approved for Chemo-Induced Diarrhea

    ACCESSWIRE

    Jaguar Health Participates in Pet Connect Conference for NP300

    ACCESSWIRE

    Jaguar Health to Present at NobleCon20 and Growth Conference

    ACCESSWIRE

    Jaguar Seeks Partner for NP300 Antisecretory Drug for Dog Diarrhea

    ACCESSWIRE

    Jaguar Health Reports Third Quarter 2024 Financial Results

    ACCESSWIRE

    Jaguar Health to Hold Q3 2024 Financial Webcast on Nov 13

    ACCESSWIRE

    FDA Approves Canalevia for Chemotherapy-Induced Diarrhea in Dogs

    ACCESSWIRE

    Jaguar`s Crofelemer Shows Positive IBS-D Results at ACG Meeting

    ACCESSWIRE

    Jaguar Health Launches FDA-Approved Gelclair In The U.S.

    ACCESSWIRE

    Jaguar Announces Inducement Grants Under Nasdaq Rule

    ACCESSWIRE

    Magdalena Biosciences To Present At BIO Investor Forum Oct 16

    ACCESSWIRE

    Jaguar Health Submits Abstract For Cancer Diarrhea Study

    ACCESSWIRE

    Jaguar Health Reports Positive Phase 3 Results For Crofelemer

    ACCESSWIRE

    Jaguar Health To Present At MedInvest Conference

    ACCESSWIRE

    Jaguar Health Appoints Veteran To Lead Oncology, HIV Sales

    ACCESSWIRE

    Jaguar Health To Present At H.C. Wainwright Conference

    ACCESSWIRE

    Jaguar Health Gets New Hong Kong Patent For Short Bowel Syndrome Treatment

    ACCESSWIRE

    Jaguar Health To Hold Investor Webcast On Q2 Earnings And Trial Results

    ACCESSWIRE

    Jaguar Health To Explore Crofelemer For Breast And Lung Cancer

    ACCESSWIRE

    Napo Pharma Gets EU Patent For Crofelemer In CDD-Related Diarrhea

    PHARMABIZ

    Jaguar Health`s Elisabetsky To Speak On Plant-Based Schizophrenia Meds

    ACCESSWIRE

    Jaguar Health`s Crofelemer Shows Positive Results For IBS-D Diarrhea

    ACCESSWIRE

    Jaguar Health Receives New European Patent For CDD Treatment

    ACCESSWIRE

    Jaguar Health To Report Phase 3 Crofelemer Results On July 23

    ACCESSWIRE

    Jaguar Health Strengthens IP With New Patents For SBS And CDD Treatments

    ACCESSWIRE

    Jaguar Health Regains Compliance with Nasdaq`s Bid Price Requirement

    ACCESSWIRE

    Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting

    ACCESSWIRE

    Jaguar Health To Report Phase 3 OnTarget Trial Results By July 23

    ACCESSWIRE

    Jaguar Health Reports New Employee Inducement Grant

    ACCESSWIRE

    Jaguar Out-Licenses Botanical Candidate For Schizophrenia To JV

    ACCESSWIRE

    Jaguar Health: Positive Crofelemer Trial Results For Functional Diarrhea

    ACCESSWIRE

    Jaguar Gelclair Asco Launch: Oral Mucositis Product Exhibit Debut

    ACCESSWIRE

    Jaguar Health, Inc. Announces Reverse Stock Split

    ACCESSWIRE

    Jaguar Health Reports First Quarter 2024 Financial Results

    ACCESSWIRE

    Jaguar Health Webcast On Q1 2024 Financials, Corporate Update On May 14

    ACCESSWIRE

    Jaguar MVID, SBS Trial Applications In Europe

    ACCESSWIRE

    Jaguar Health To Host Webcast On Q1 2024 Financials, Updates

    ACCESSWIRE

    Crofelemer receives FDA conditional approval for chemotherapy-induced diarrhea

    ACCESSWIRE

    Napo Sponsors MVID Panel at Pedia GI Conference in Abu Dhabi

    ACCESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.